Form 4 Filing by Cecilia Jones, Chief Financial Officer of Agios Pharmaceuticals, Inc.

Cecilia Jones, Chief Financial Officer of Agios Pharmaceuticals, Inc., reported transactions on April 2, 2026. Jones acquired 8,500 shares of Common stock through the vesting of performance share units, which were granted on March 1, 2024, and vested upon the achievement of a specified regulatory milestone. The performance share units were settled on April 2, 2026, with each unit representing a contingent right to one share of common stock. Concurrently, Jones sold 3,141 shares of Common stock at a price of $34.71 per share to cover tax withholding obligations related to the vesting of her performance share units. These sales were executed under automatic sale instructions consistent with Rule 10b5-1(c) of the Securities Exchange Act of 1934. Following these transactions, Jones holds 54,998 shares of common stock. Additionally, 311 shares were purchased through the Company's employee stock purchase plan.